Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4
inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
Phase:
Phase 4
Details
Lead Sponsor:
VU University Medical Center
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Glimepiride Linagliptin